About Pathios
Pathios is a company based in Oxford (United Kingdom) founded in 2017 by Alan Naylor and Peter Joyce was acquired by Sygnature Discovery in February 2019.. Pathios has raised $90.81 million across 9 funding rounds from investors including Gov.uk, Sygnature Discovery and Canaan. The company has 9 employees as of January 31, 2022. Pathios offers products and services including PTT-4256. Pathios operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Oxford, United Kingdom
- Employees 9 as on 31 Jan, 2022
- Founders Alan Naylor, Peter Joyce
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pathios Therapeutics Limited
- Date of Incorporation 27 Feb, 2017
- Jurisdiction ABINGDON, ENGLAND
-
Annual Revenue
-
Net Profit
$-7.71 M (USD)-27as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$90.81 M (USD)
in 9 rounds
-
Latest Funding Round
$19 M (USD), Series B
Feb 27, 2025
-
Investors
Gov.uk
& 4 more
-
Employee Count
9
as on Jan 31, 2022
-
Acquired by
Sygnature Discovery
(Feb 13, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pathios
Pathios offers a comprehensive portfolio of products and services, including PTT-4256. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits acid-sensing receptor to reverse immune suppression in tumors
Unlock access to complete
Unlock access to complete
Funding Insights of Pathios
Pathios has successfully raised a total of $90.81M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $19 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $19.0M
-
First Round
First Round
(01 Apr 2019)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series B - Pathios | Valuation |
investors |
|
| Apr, 2024 | Amount | Series B - Pathios | Valuation |
investors |
|
| Jan, 2023 | Amount | Series B - Pathios | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pathios
Pathios has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Sygnature Discovery and Canaan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Early-stage medical companies are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pathios
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pathios
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pathios Comparisons
Competitors of Pathios
Pathios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pathios
Frequently Asked Questions about Pathios
When was Pathios founded?
Pathios was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Pathios located?
Pathios is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Is Pathios a funded company?
Pathios is a funded company, having raised a total of $90.81M across 9 funding rounds to date. The company's 1st funding round was a Series B of $8.64M, raised on Apr 01, 2019.
How many employees does Pathios have?
As of Jan 31, 2022, the latest employee count at Pathios is 9.
What does Pathios do?
Pathios was established in 2017 and is headquartered in Oxford, United Kingdom. Small molecule-based therapeutics are developed by the company within the biotechnology sector to address autoimmune diseases. The lead candidate is focused on modulating GPR65, a pH-sensing GPCR, to influence immune responses in autoimmune disorders. Operations center on advancing these candidates through research and development stages.
Who are the top competitors of Pathios?
Pathios's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
What products or services does Pathios offer?
Pathios offers PTT-4256.
Who are Pathios's investors?
Pathios has 5 investors. Key investors include Gov.uk, Sygnature Discovery, Canaan, Bristol-Myers Squibb, and Brandon Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.